Association between tumor infiltrating lymphocytes (TILs) and the HER2DX assay in early-stage of HER2-positive (HER2+) breast cancer

被引：0

作者：

Sanfeliu, Esther

Braso-Maristany, Fara

Dieci, Maria Vittoria

Marin-Aguilera, Mercedes

Gonzalez-Farre, Blanca

Griguolo, Gaia

Pascual, Tomas

Galvan, Patricia

Angelats, Laura

Castillo, Oleguer

Blasco, Paula

Sirenko, Valeria

Jares, Pedro

Puig-Butille, Joan Anton

Pare, Laia

Martinez, Antonio

Llombart-Cussac, Antonio

Cortes, Javier

Vivancos, Ana

Villagrasa, Patricia

Parker, Joel S.

Perou, Charles M.

Prat, Aleix

Conte, PierFranco

Guarneri, Valentina

机构：

来源：

CANCER RESEARCH | 2023年 / 83卷 / 05期

关键词：

D O I：

10.1158/1538-7445.SABCS22-P4-02-30

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P4-02-30

引用

页数：3

共 50 条

[1] Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer
Marin-Aguilera, M.
Jares, P.
Sanfeliu, E.
Villacampa, G.
Hernandez-lllan, E.
Martinez-Puchol, A. I.
Shankar, S.
Gonzalez-Farre, B.
Waks, A. G.
Braso-Maristany, F.
Pardo, F.
Manning, D. K.
Abery, J. A.
Curaba, J.
Moon, L.
Gordon, O.
Galvan, P.
Wachirakantapong, P.
Castillo, O.
Nee, C. M.
Blasco, P.
Senevirathne, T. H.
Sirenko, V.
Martinez-Saez, O.
Aguirre, A.
Krop, I. E.
Li, Z.
Spellman, P.
Metzger Filho, O.
Polyak, K.
Michaels, P.
Puig-Butille, J. A.
Vivancos, A.
Matito, J.
Buckingham, W.
Perou, C. M.
Villagrasa-Gonzalez, P.
Prat, A.
Parker, J. S.
Pare, L.
[J]. ESMO OPEN, 2024, 9 (03)
[2] Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+BC)
Loi, S.
Michiels, S.
Salgado, R.
Sirtaine, N.
Jose, V.
Fumagalli, D.
Brown, D. N.
Kellokumpu-Lehtinen, P-L
Bono, P.
Kataja, V.
Desmedt, C.
Piccart-Gebhart, M. J.
Loibl, S.
Untch, M.
Denkert, C.
Smyth, M. J.
Joensuu, H.
Sotiriou, C.
[J]. CANCER RESEARCH, 2013, 73
[3] HER2DX genomic assay in advanced HER2-positive (HER2+) breast cancer treated with T-DM1
Braso-Maristany, F.
Griguolo, G.
Chic, N.
Pare Brunet, L.
Galvan, P.
Dieci, M. V.
Miglietta, F.
Giarratano, T.
Martinez-Saez, O.
Marin, M.
Vidal Losada, M. J.
Adamo, B.
Munoz, M.
Vivancos, A.
Villagrasa Gonzalez, P.
Parker, J.
Perou, C. M.
Conte, P. F.
Prat, A.
Guarneri, V.
[J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S646 - S646
[4] Investigating HER2DX genomic assay concordance within HER2-positive breast cancer
Braso-Maristany, Fara
Pare, Laia
Villacampa, Guillermo
Marin-Aguilera, Mercedes
Spellman, Paul
Waks, Adrienne
Krop, Ian
Sanfeliu, Esther
Li, Zhequi
Galvan, Patricia
Hernandez-Illan, Eva
Jares, Pedro
Puig-Butille, Joan Anton
Vivancos, Ana
Villagrasa, Patricia
Parker, Joel S.
Perou, Charles M.
Tolaney, Sara
Metzger, Otto
Polyak, Kornelia
Prat, Aleix
[J]. CANCER RESEARCH, 2024, 84 (09)
[5] HER2DX: Advances in targeted treatment of HER2-positive breast cancer
Andujar, Juan M. Cejalvo
[J]. REVISTA DE SENOLOGIA Y PATOLOGIA MAMARIA, 2024, 37 (03):
[6] Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
Prat, Aleix
Guarneri, Valentina
Pascual, Tomas
Braso-Maristany, Fara
Sanfeliu, Esther
Pare, Laia
Schettini, Francesco
Martinez, Debora
Jares, Pedro
Griguolo, Gaia
Dieci, Maria Vittoria
Cortes, Javier
Llombart-Cussac, Antonio
Conte, Benedetta
Marin-Aguilera, Mercedes
Chic, Nuria
Puig-Butille, Joan Anton
Martinez, Antonio
Galvan, Patricia
Tsai, Yi-Hsuan
Gonzalez-Farre, Blanca
Mira, Aurea
Vivancos, Ana
Villagrasa, Patricia
Parker, Joel S.
Conte, Pierfranco
Perou, Charles M.
[J]. EBIOMEDICINE, 2022, 75
[7] Dynamics of tumor-infiltrating lymphocytes (TILs) during neoadjuvant dual HER2 blockade in HER2-positive (HER2+) breast cancer in the absence of chemotherapy
Griguolo, G.
Holgado, E.
Cortes, J.
Fasani, R.
Pascual, T.
Pare, L.
Bermejo, B.
Oliveira, M.
Morales, S.
Martinez, N.
Vidal, M.
Pernas, S.
Lopez, R.
Munoz, M.
Galvan, P.
Garau, I.
Manso, L.
Alarcon, J.
Martinez, E.
Villagrasa, P.
LLombart-Cussac, A.
[J]. CANCER RESEARCH, 2019, 79 (04)
[8] Research-based HER2DX in patients with early-stage HER2-positive (HER2+) breast cancer treated in the N9831 phase III clinical trial
Braso-Maristany, F.
Martinez Saez, O.
Pare Brunet, L.
Marin-Aguilera, M.
Conte, P. F.
Jares, P.
Guarneri, V.
Pascual, T.
Puig-Butille, J. A.
Vivancos, A.
Parker, J.
Villagrasa Gonzalez, P.
Tolaney, S. M.
Carey, L. A.
Perou, C. M.
Prat, A.
[J]. ANNALS OF ONCOLOGY, 2022, 33 : S134 - S135
[9] Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
Villacampa, G.
Tung, N. M.
Pernas, S.
Pare, L.
Bueno-Muino, C.
Echavarria, I.
Lopez-Tarruella, S.
Roche-Molina, M.
del Monte-Millan, M.
Marin-Aguilera, M.
Braso-Maristany, F.
Waks, A. G.
Pascual, T.
Martinez-Saez, O.
Vivancos, A.
Conte, P. F.
Guarneri, V.
Dieci, M. Vittoria
Griguolo, G.
Cortes, J.
Llombart-Cussac, A.
Munoz, M.
Vidal, M.
Adamo, B.
Wolff, A. C.
Demichele, A.
Villagrasa, P.
Parker, J. S.
Perou, C. M.
Fernandez-Martinez, A.
Carey, L. A.
Mittendorf, E. A.
Martin, M.
Prat, A.
Tolaney, S. M.
[J]. ANNALS OF ONCOLOGY, 2023, 34 (09) : 783 - 795
[10] Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial
Nuciforo, P.
Prat, A.
Llombart, A.
Fasani, R.
Pare, L.
Pascual, T.
Oliveira, M.
Martinez Janez, N.
Bermejo De las Heras, B.
Vidal, M.
Pernas Simon, S.
Lopez, R.
Munoz, M.
Garau, I.
Manso, L.
Alarcon Company, J.
Martinez de Duenas, E.
Villagrasa Gonzalez, P.
Cortes Castan, J.
Holgado, E.
[J]. ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →